Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

Cancer treatment, oncology drug access, hematologic malignancies, and cancer drug policy.

Specific solid tumor cancer types organized by organ system and tissue origin.